Plain English Summary
Background and study aims
While there are many ideas about the effects of diet on the risk of developing cancer and other diseases, understanding of the health effects of diet is far from complete. The aim of this study is to examine the effects of diet on the risk of developing cancer and other diseases, including but not limited to cardiovascular (heart) diseases, metabolic disorders, bone health, and gastrointestinal (digestive system) diseases.
Who can participate?
Men and women who live within reasonable travelling distance (about 25 km) of one of the 22 assessment centres
What does the study involve?
Participants attend a clinical visit during which lifestyle and physical measurements are taken. Their health data records are used to assess the links between various dietary factors (e.g. nutrients and food intakes or habitual diet groups) and incidence or mortality (death) from cancer or other diseases, with follow-up until December 2014 in the first instance, and with additional follow-up as this information is collected.
What are the possible benefits and risks of participating?
There are no expected benefits or risks of participation except for the time required for the clinical visit (about 90 minutes).
Where is the study run from?
University of Oxford (UK)
When is the study starting and how long is it expected to run for?
September 2004 to December 2014
Who is funding the study?
1. Medical Research Council (UK)
2. Wellcome Trust (UK)
Who is the main contact?
Dr Kathryn Bradbury
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
UK Biobank project number 3037
Study information
Scientific title
Diet and risk of cancer and other diseases in the UK Biobank: a longitudinal cohort study
Acronym
Study hypothesis
To develop a research programme on diet in UK Biobank, to study the effects of diet on the risk of cancer and other diseases.
Ethics approval
Permission for access to patient records for recruitment was approved by the Patient Information Advisory Group (subsequently replaced by the National Information Governance Board for Health and Social Care) in England and Wales, and the Community Health Index Advisory Group in Scotland, 17/06/2011, ref: 11/NW/0382
Study design
Longitudinal cohort study
Primary study design
Observational
Secondary study design
Longitudinal study
Trial setting
Other
Trial type
Other
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Condition
Cancer and other diseases or conditions, including but not limited to cardiovascular diseases, metabolic disorders, bone health, anaemia, gastrointestinal disease, and intermediate markers of health related to the above diseases, such as anthropometry, physical characteristics and biomarkers
Intervention
The trialists will be assessing the association between various dietary factors (e.g. nutrients and food intakes or habitual diet groups) and incidence or mortality from cancer or other diseases, including but not limited to cardiovascular diseases, metabolic disorders, bone health, and gastrointestinal diseases, and characterisation of intermediate markers, either as cross-sectional analyses or longitudinal analyses with follow-up until December 2014 in the first instance, and subsequently with additional follow-up as this information is accrued.
Intervention type
Phase
Drug names
Primary outcome measure
Incidence or mortality from cancer, measured via record linkage to hospital records or death registries longitudinally for indefinite periods at whichever time point the event occurs
Secondary outcome measures
1. Incidence or mortality from other diseases, including but not limited to cardiovascular diseases, metabolic disorders, bone health, and gastrointestinal diseases, measured via record linkage to hospital records or death registries longitudinally for indefinite periods at whichever time point the event occurs
2. Intermediate markers: anthropometric measures (bio-impedance and DEXA scans), bone mineral density (heel bone ultrasound), blood pressure and pulse rate (blood pressure monitor), grip strength (dynamometer), and blood counts (various assays), measured at baseline
Overall trial start date
14/09/2004
Overall trial end date
31/12/2014
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Men and women who lived within reasonable travelling distance (~25 km) of one of the 22 assessment centres
Participant type
All
Age group
Adult
Gender
Both
Target number of participants
500000
Participant exclusion criteria
No pre-specified exclusion criteria
Recruitment start date
13/03/2006
Recruitment end date
01/10/2010
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Cancer Epidemiology Unit, University of Oxford
OX3 7LF
Funders
Funder type
Research council
Funder name
Medical Research Council
Alternative name(s)
MRC
Funding Body Type
government organisation
Funding Body Subtype
Federal/National Government
Location
United Kingdom
Funder name
Wellcome Trust
Alternative name(s)
Wellcome
Funding Body Type
private sector organisation
Funding Body Subtype
international
Location
United Kingdom
Funder name
Girdlers New Zealand Health Research Council
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
For further details of the UK Biobank study protocol and recruitment methods, please visit http://www.ukbiobank.ac.uk/resources/. Other resources will not be publicly available but researchers are welcome to send in enquiries to the corresponding author. Multiple publications planned in peer-reviewed journals from October 2017 onwards.
IPD sharing statement
UK Biobank is an open access resource. Bona fide researchers can obtain further information or apply to use the UK Biobank dataset by registering and applying at http://www.ukbiobank.ac.uk/register-apply/.
Intention to publish date
31/10/2017
Participant level data
Available on request
Basic results (scientific)
Publication list
2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/29868910